Peginterferon Lambda Accelerates SARS-CoV-2 Decline in Outpatients
TUESDAY, Feb. 9, 2021 -- For outpatients with COVID-19, peginterferon lambda accelerates viral decline, according to a study published online Feb. 5 in The Lancet Respiratory Medicine.
Jordan J. Feld, M.D., from the Toronto Centre for Liver Disease, and colleagues conducted a double-blind, placebo-controlled phase 2 trial involving outpatients with laboratory-confirmed COVID-19. Participants were randomly assigned to either a single subcutaneous injection of peginterferon lambda or placebo in a 1:1 ratio (30 patients per group).
The researchers found that from day 3 onward, the decline in severe acute respiratory syndrome coronavirus 2 RNA was greater for those treated with peginterferon lambda than placebo, with a difference of 2.42 log copies/mL at day 7 (P = 0.0041). By day 7, 80 and 63 percent of participants in the peginterferon lambda and placebo groups, respectively, had an undetectable viral load (P = 0.15). Patients in the peginterferon lambda group were significantly more likely to have undetectable viral load by day 7 after controlling for baseline viral load (odds ratio, 4.12; 95 percent confidence interval, 1.15 to 16.73; P = 0.029). Overall, 79 and 38 percent of those with baseline viral load greater than 106 copies/mL had undetectable virus on day 7 in the peginterferon lambda and placebo groups, respectively (odds ratio, 6.25; 95 percent confidence interval, 1.49 to 31.06; P = 0.012).
"This treatment might have potential to avert clinical deterioration, shorten the duration of infectiousness, and reduce isolation time, with substantial public health and societal effects," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including Eiger BioPharmaceuticals, which supplied the study medication.
© 2021 HealthDay. All rights reserved.
Posted: February 2021
Further Support and Information on COVID-19
Read this next
TUESDAY, March 2, 2021 -- Individuals with previous severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection generate strong responses to one dose of the BNT162b2...
TUESDAY, March 2, 2021 -- Eight in 10 older adults say they have not been screened for hearing loss in primary care within the last two years, according to a report published...
TUESDAY, March 2, 2021 -- Treatment with interleukin-6 receptor antagonists tocilizumab and sarilumab improves outcomes among critically ill patients with COVID-19 receiving organ...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.